Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
FWB: CWY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
15
February
2023
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Read More
8
February
2023
Israel-Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More
31
January
2023
Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
Read More
25
January
2023
Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Read More
19
January
2023
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company
Read More
17
January
2023
Israel-Based Clearmind Announces Additional Positive Results from the its Pre-Clinical Study for Cocaine Addiction Treatment
Read More
10
January
2023
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
Read More
5
January
2023
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Pre-Clinical Trial
Read More
28
December
2022
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
Read More
21
December
2022
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
Read More
15
December
2022
Israeli Biotech Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
Read More
13
December
2022
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
Read More
9
December
2022
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
Read More
23
November
2022
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
Read More
17
November
2022
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
Read More
Previous
Next
